EGFR and non-small cell lung carcinoma: Twenty‐five patients with NSCLC positive for EGFR activating mutations who had tissue and plasma specimens collected before treatment with EGFR‐TKIs or after the development of resistance to these drugs were enrolled in the study (Table 1).